Erschienen in:
01.12.2009 | Clinical trial
Correlation of HER2 status between primary tumors and corresponding circulating tumor cells in advanced breast cancer patients
verfasst von:
Marta Pestrin, Silvia Bessi, Francesca Galardi, Mara Truglia, Annibale Biggeri, Chiara Biagioni, Silvia Cappadona, Laura Biganzoli, Augusto Giannini, Angelo Di Leo
Erschienen in:
Breast Cancer Research and Treatment
|
Ausgabe 3/2009
Einloggen, um Zugang zu erhalten
Abstract
Biocharacterization of circulating tumor cells (CTCs) in the peripheral blood of advanced breast cancer (ABC) patients may represent a real-time tumor biopsy. We assessed HER2 status on CTCs from blood samples of ABC patients. CTCs were separated and stained using the CellSearch System®. HER2 status was assessed by immunofluorescence and, when technically feasible, by fluorescence in situ hybridization. Blood samples were obtained from 66 ABC patients. Forty patients had a positive CTC sample (61%) and of these, 15 (37%) had HER2 + CTCs. We found non-concordant results in 32% of cases: 29% (8/28) of HER2-negative primary tumors had HER2-positive CTCs and 42% (5/12) of HER2-positive primary tumors had HER2-negative CTCs (k = 0.278). Our study suggests that a subset of patients with HER2-negative primary tumors develops HER2-positive CTCs during disease progression.